You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歐康維視生物-B(01477.HK):OT-502在中國獲批III期臨牀試驗
格隆匯 07-08 19:20

格隆匯7月8日丨歐康維視生物-B(01477.HK)發佈公吿,集團在中國申請啟動集團的主要候選藥物之一OT-502 (DEXYCU®)的III期臨牀試驗近期獲中國國家藥品監督管理局藥品審評中心受理。

根據披露,DEXYCU®於2018年2月9日在美國獲得美國食品藥品監督管理局(“FDA”)批准上市,是第一個也是唯一一個FDA批准的治療術後炎症適應症的眼內緩釋藥物。炎症是白內障手術後常見的症狀,如果不及時治療可能會導致嚴重的併發症。迄今為止,臨牀上常規使用激素和抗生素滴眼液二至四周來治療術後炎症,但白內障患者多為老年人,用藥依從性較差。利用藥物遞送平台Verisome®,OT-502 (DEXYCU®)可將地塞米松遞送至前房,直接抑制前房內炎症介質的合成和釋放,較好地抑制了術後前房炎症反應,避免了局部激素滴眼液的頻繁使用,有效解決了患者白內障術後用藥依從性不佳的問題,為白內障術後炎症管理提供了更好的治療選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account